Relay Therapeutics Inc (NASDAQ: RLAY) on Friday, plunged -1.46% from the previous trading day, before settling in for the closing price of $4.78. Within the past 52 weeks, RLAY’s price has moved between $4.25 and $12.14.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 319.82% over the last five years. The company achieved an average annual earnings per share of 9.80%. With a float of $123.26 million, this company’s outstanding shares have now reached $166.89 million.
The firm has a total of 323 workers. Let’s measure their productivity. In terms of profitability, gross margin is 58.64%, operating margin of -3926.55%, and the pretax margin is -3449.92%.
Relay Therapeutics Inc (RLAY) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Relay Therapeutics Inc is 26.36%, while institutional ownership is 73.16%. The most recent insider transaction that took place on Oct 28 ’24, was worth 9,823. In this transaction an insider of this company sold 1,621 shares at a rate of $6.06, taking the stock ownership to the 390,063 shares. Before that another transaction happened on Oct 28 ’24, when Company’s Chief Financial Officer sold 6,802 for $6.06, making the entire transaction worth $41,220. This insider now owns 306,391 shares in total.
Relay Therapeutics Inc (RLAY) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 9.80% per share during the next fiscal year.
Relay Therapeutics Inc (NASDAQ: RLAY) Trading Performance Indicators
Relay Therapeutics Inc (RLAY) is currently performing well based on its current performance indicators. A quick ratio of 18.42 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 77.60.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.61, a number that is poised to hit -0.57 in the next quarter and is forecasted to reach -2.64 in one year’s time.
Technical Analysis of Relay Therapeutics Inc (RLAY)
Analysing the last 5-days average volume posted by the [Relay Therapeutics Inc, RLAY], we can find that recorded value of 3.83 million was better than the volume posted last year of 1.54 million. As of the previous 9 days, the stock’s Stochastic %D was 66.29%. Additionally, its Average True Range was 0.34.
During the past 100 days, Relay Therapeutics Inc’s (RLAY) raw stochastic average was set at 7.11%, which indicates a significant decrease from 50.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 74.65% in the past 14 days, which was lower than the 92.79% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.62, while its 200-day Moving Average is $6.92. Now, the first resistance to watch is $4.85. This is followed by the second major resistance level at $4.99. The third major resistance level sits at $5.14. If the price goes on to break the first support level at $4.57, it is likely to go to the next support level at $4.42. Now, if the price goes above the second support level, the third support stands at $4.28.
Relay Therapeutics Inc (NASDAQ: RLAY) Key Stats
Market capitalization of the company is 776.82 million based on 167,383K outstanding shares. Right now, sales total 25,550 K and income totals -341,970 K. The company made 0 K in profit during its latest quarter, and -92,210 K in sales during its previous quarter.
